MX2010005070A - Derivados de piridazinona como inhibidores de parp. - Google Patents
Derivados de piridazinona como inhibidores de parp.Info
- Publication number
- MX2010005070A MX2010005070A MX2010005070A MX2010005070A MX2010005070A MX 2010005070 A MX2010005070 A MX 2010005070A MX 2010005070 A MX2010005070 A MX 2010005070A MX 2010005070 A MX2010005070 A MX 2010005070A MX 2010005070 A MX2010005070 A MX 2010005070A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- parp inhibitors
- cancer
- pyridazinone derivatives
- treatment
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010057430 Retinal injury Diseases 0.000 abstract 1
- 206010038997 Retroviral infections Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009758 senescence Effects 0.000 abstract 1
- 230000037380 skin damage Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0722401A GB0722401D0 (en) | 2007-11-15 | 2007-11-15 | Therapeutic compounds |
| GB0816707A GB0816707D0 (en) | 2008-09-12 | 2008-09-12 | Therapeutic compounds |
| PCT/GB2008/051063 WO2009063244A1 (en) | 2007-11-15 | 2008-11-14 | Pyridazinone derivatives as parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010005070A true MX2010005070A (es) | 2010-05-24 |
Family
ID=40427149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010005070A MX2010005070A (es) | 2007-11-15 | 2008-11-14 | Derivados de piridazinona como inhibidores de parp. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8268827B2 (enExample) |
| EP (1) | EP2220073B1 (enExample) |
| JP (1) | JP5758630B2 (enExample) |
| KR (1) | KR101641596B1 (enExample) |
| CN (1) | CN101855221B (enExample) |
| AU (1) | AU2008322676B9 (enExample) |
| CA (1) | CA2704714C (enExample) |
| ES (1) | ES2524787T3 (enExample) |
| IL (1) | IL205142A (enExample) |
| MX (1) | MX2010005070A (enExample) |
| NZ (1) | NZ585395A (enExample) |
| RU (1) | RU2490265C2 (enExample) |
| WO (1) | WO2009063244A1 (enExample) |
| ZA (1) | ZA201002466B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2623491A3 (en) * | 2009-04-02 | 2014-07-30 | Merck Patent GmbH | Piperidine and piperazine derivatives as autotaxin inhibitors |
| US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| EP2686305B1 (en) * | 2011-03-14 | 2020-09-16 | Impact Therapeutics, Inc. | Quinazolinediones and their use |
| EP2714703B1 (en) | 2011-05-31 | 2021-03-10 | Newgen Therapeutics, Inc. | Tricyclic inhibitors of poly(adp-ribose)polymerase |
| RS56616B1 (sr) | 2011-12-31 | 2018-02-28 | Beigene Ltd | Kondenzovani tetra ili penta-ciklični dihidrodiazepinokarbazoloni kao parp inhibitori |
| NZ626937A (en) | 2011-12-31 | 2016-09-30 | Beigene Ltd | Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors |
| EP2804602B1 (en) | 2012-01-20 | 2024-12-04 | Del Mar Pharmaceuticals | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma |
| CA2880896C (en) | 2012-06-26 | 2021-11-16 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| WO2014102817A1 (en) | 2012-12-31 | 2014-07-03 | Cadila Healthcare Limited | Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| CA2938626A1 (en) | 2013-07-26 | 2015-01-29 | John Rothman | Compositions to improve the therapeutic benefit of bisantrene |
| KR101670126B1 (ko) | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| CA2946538A1 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| FR3027901B1 (fr) * | 2014-10-31 | 2018-03-16 | Universite De Reims Champagne Ardenne | Nouveaux procedes appartenant a la famille des pyridazinones. |
| WO2016096709A1 (en) | 2014-12-16 | 2016-06-23 | Eudendron S.R.L. | Heterocyclic derivatives modulating activity of certain protein kinases |
| RS59934B1 (sr) * | 2015-06-09 | 2020-03-31 | Abbvie Inc | Modulatori nuklearnih receptora (ror) za lečenje inflamatornih i autoimunih oboljenja |
| HK1249504A1 (zh) * | 2015-09-02 | 2018-11-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | 用作溴结构域抑制剂的吡啶酮二甲酰胺 |
| CN108290843B (zh) | 2015-10-01 | 2021-08-24 | 百时美施贵宝公司 | 联芳基激酶抑制剂 |
| KR102030016B1 (ko) | 2016-09-05 | 2019-10-08 | 충남대학교산학협력단 | 신규한 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 |
| PT3448859T (pt) | 2017-03-20 | 2019-10-25 | Forma Therapeutics Inc | Composições de pirrolopirrole como ativadores de piruvato quinase (pkr). |
| CN108383837B (zh) * | 2018-02-09 | 2020-08-11 | 福建医科大学 | 一种氨基取代四氢吡啶并嘧啶类化合物或其可用盐及其制备方法与应用 |
| EA202092590A1 (ru) * | 2018-04-30 | 2021-04-08 | Рибон Терапьютикс Инк. | Пиридазиноны в качестве ингибиторов parp7 |
| WO2019212946A1 (en) | 2018-04-30 | 2019-11-07 | Ribon Therapeutics Inc. | Screening methods for parp modulators |
| KR102017115B1 (ko) | 2018-05-15 | 2019-09-02 | 충남대학교산학협력단 | 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| WO2020223229A1 (en) | 2019-04-29 | 2020-11-05 | Ribon Therapeutics, Inc. | Solid forms of a parp7 inhibitor |
| CN110818908B (zh) * | 2019-08-29 | 2021-12-17 | 杭州市富阳区浙工大银湖创新创业研究院 | 一种用于检测氧化气体的金属有机骨架材料的制备方法 |
| CN114615977B (zh) | 2019-09-19 | 2025-01-14 | 诺沃挪第克健康护理股份公司 | 丙酮酸激酶r(pkr)活化组合物 |
| KR20220109401A (ko) * | 2019-10-30 | 2022-08-04 | 리본 테라퓨틱스 인코포레이티드 | Parp7 억제제로서의 피리다진온 |
| KR102293986B1 (ko) | 2019-10-30 | 2021-08-26 | 충남대학교산학협력단 | 이소퀴놀리논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 |
| US20240190844A1 (en) * | 2019-10-30 | 2024-06-13 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
| CA3176219A1 (en) | 2020-04-21 | 2021-10-28 | Kunhee LEE | Crystalline forms of phthalazinone compound |
| JP7626783B2 (ja) | 2020-04-21 | 2025-02-07 | アイディーエンス カンパニー リミテッド | フタラジノン誘導体及びその中間体を調製するプロセス |
| WO2021224186A1 (en) * | 2020-05-04 | 2021-11-11 | Institut Curie | New pyridine derivatives as radiosensitizers |
| US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| CN117425648A (zh) * | 2021-03-12 | 2024-01-19 | 杭州英创医药科技有限公司 | 作为parp7抑制剂的化合物 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| AU2022248850A1 (en) | 2021-03-27 | 2023-11-09 | TRx Biosciences Limited | Compositions having improved bioavailability of therapeutics |
| CN115477640A (zh) * | 2021-05-31 | 2022-12-16 | 由理生物医药（上海）有限公司 | 作为parp7抑制剂的哒嗪酮类化合物 |
| CN117751108A (zh) * | 2021-07-21 | 2024-03-22 | 南京明德新药研发有限公司 | 哒嗪酮类化合物 |
| CA3226796A1 (en) * | 2021-07-29 | 2023-02-02 | Xiaoxia Yan | Novel parp7 inhibitor and use thereof |
| CN117279907A (zh) * | 2021-08-06 | 2023-12-22 | 成都百裕制药股份有限公司 | 吡咯烷酮衍生物及其在医药上的应用 |
| JP2024539252A (ja) * | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| CN115745971B (zh) * | 2021-12-20 | 2024-07-30 | 北京华森英诺生物科技有限公司 | Parp7抑制剂及其应用 |
| CN116375688B (zh) * | 2021-12-23 | 2025-04-11 | 中国药科大学 | 哒嗪酮类化合物及其制备方法、药物组合物和应用 |
| IL315617A (en) * | 2022-03-14 | 2024-11-01 | Trx Biosciences Ltd | Preparations with improved bioavailability of drugs and their uses |
| JP7763538B2 (ja) * | 2022-04-01 | 2025-11-04 | 諾沃斯達薬業（上海）有限公司 | Ｐａｒｐ７阻害剤及びその使用 |
| WO2024073133A1 (en) * | 2022-09-30 | 2024-04-04 | Azkarra Therapeutics, Inc. | Pyridazin-3(2h)-one and pyridin-2(1h)-one parp inhibitor compounds |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025087383A1 (zh) * | 2023-10-26 | 2025-05-01 | 深圳众格生物科技有限公司 | 作为parp7抑制剂的化合物 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622948A (en) * | 1994-12-01 | 1997-04-22 | Syntex (U.S.A.) Inc. | Pyrrole pyridazine and pyridazinone anti-inflammatory agents |
| IL118631A (en) * | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
| CN1136197C (zh) | 1996-05-30 | 2004-01-28 | 霍夫曼-拉罗奇有限公司 | 新的哒嗪酮衍生物 |
| HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| EP1397350B1 (en) | 2001-05-08 | 2007-02-28 | Kudos Pharmaceuticals Limited | Isoquinolinone derivatives as parp inhibitors |
| AU2003229953A1 (en) | 2002-04-30 | 2003-11-17 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| BRPI0408284B8 (pt) * | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
| EP1608629A1 (en) * | 2003-03-24 | 2005-12-28 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
| WO2005082368A1 (en) | 2004-02-26 | 2005-09-09 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
| CA2559552A1 (en) | 2004-03-23 | 2005-09-29 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors |
| PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| CA2563225A1 (en) * | 2004-04-15 | 2005-10-27 | F. Hoffmann-La Roche Ag | Process for preparing pyridazinone compounds |
| MX2007002318A (es) | 2004-08-26 | 2007-04-17 | Kudos Pharm Ltd | Derivados de ftalazinona substituidos con 4-heteroarilmetilo. |
| CA2614529C (en) | 2005-07-21 | 2011-06-28 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives as thyroid hormone receptor agonists |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| US8466150B2 (en) * | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| DK2120579T3 (da) * | 2006-12-28 | 2014-02-03 | Abbvie Inc | Inhibitorer af poly(ADP-ripose)polymerase |
| US20080280910A1 (en) | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| TW200900396A (en) | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US20090023727A1 (en) | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
-
2008
- 2008-11-14 MX MX2010005070A patent/MX2010005070A/es active IP Right Grant
- 2008-11-14 AU AU2008322676A patent/AU2008322676B9/en active Active
- 2008-11-14 US US12/739,262 patent/US8268827B2/en active Active
- 2008-11-14 NZ NZ585395A patent/NZ585395A/en unknown
- 2008-11-14 WO PCT/GB2008/051063 patent/WO2009063244A1/en not_active Ceased
- 2008-11-14 CA CA2704714A patent/CA2704714C/en active Active
- 2008-11-14 RU RU2010123874/04A patent/RU2490265C2/ru active
- 2008-11-14 CN CN2008801155905A patent/CN101855221B/zh active Active
- 2008-11-14 KR KR1020107013113A patent/KR101641596B1/ko active Active
- 2008-11-14 JP JP2010533666A patent/JP5758630B2/ja active Active
- 2008-11-14 EP EP08850429.5A patent/EP2220073B1/en active Active
- 2008-11-14 ES ES08850429.5T patent/ES2524787T3/es active Active
-
2010
- 2010-04-08 ZA ZA2010/02466A patent/ZA201002466B/en unknown
- 2010-04-15 IL IL205142A patent/IL205142A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US8268827B2 (en) | 2012-09-18 |
| AU2008322676B2 (en) | 2013-12-05 |
| CN101855221A (zh) | 2010-10-06 |
| CA2704714A1 (en) | 2009-05-22 |
| IL205142A0 (en) | 2010-11-30 |
| AU2008322676A1 (en) | 2009-05-22 |
| JP5758630B2 (ja) | 2015-08-05 |
| EP2220073A1 (en) | 2010-08-25 |
| US20100261709A1 (en) | 2010-10-14 |
| NZ585395A (en) | 2012-03-30 |
| CA2704714C (en) | 2018-12-04 |
| KR20100087220A (ko) | 2010-08-03 |
| BRPI0820236A2 (pt) | 2015-06-16 |
| KR101641596B1 (ko) | 2016-07-21 |
| ES2524787T3 (es) | 2014-12-12 |
| RU2490265C2 (ru) | 2013-08-20 |
| CN101855221B (zh) | 2013-10-30 |
| WO2009063244A1 (en) | 2009-05-22 |
| JP2011503166A (ja) | 2011-01-27 |
| IL205142A (en) | 2014-09-30 |
| EP2220073B1 (en) | 2014-09-03 |
| ZA201002466B (en) | 2010-12-29 |
| RU2010123874A (ru) | 2011-12-20 |
| AU2008322676B9 (en) | 2014-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010005070A (es) | Derivados de piridazinona como inhibidores de parp. | |
| WO2007138351A3 (en) | Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp) | |
| MX2009007200A (es) | Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp). | |
| MY147789A (en) | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors | |
| WO2008017883A3 (en) | 4-oxo-4,5-dihydropyrrolo[1,2-a] quinoxaline derivatives as inhibitors of poly(adp-ribose)polymerase(parp) | |
| WO2008103277A3 (en) | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors | |
| WO2006106326A8 (en) | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors | |
| ATE543811T1 (de) | Pyridazinderivate als faktor-xia-inhibitoren | |
| WO2008022286A3 (en) | Small molecule inhibitors of kynurenine-3-monooxygenase | |
| MX2009002171A (es) | Derivados de triazol como inhibidores de cinasas. | |
| WO2010021918A8 (en) | Compounds as kinase inhibitors | |
| EP2012780A4 (en) | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES AS POTENTE PARP HEMMER | |
| WO2011147951A8 (en) | Cycloamino derivatives as gpr119 agonists | |
| MX2010005650A (es) | Derivados de diazabicicloalcano substituidos con biarilo. | |
| WO2007076228A3 (en) | 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders | |
| WO2008086128A3 (en) | Aminopyrazole kinase inhibitors | |
| WO2008084067A3 (en) | Pharmaceutically active dihydrobenzofurane-substituted benzimidazole derivatives | |
| TH141815A (th) | สารยับยั้งไคเนสซึ่งมีโพรไฟล์ด้านความปลอดภัยของ cyp ที่ดีขึ้น | |
| WO2009005469A3 (en) | The use of compounds such as pyridoxal derivatives for the treatment of diabetes or diseases associated with the metabolic syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GB | Transfer or rights |